GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zenas Biopharma ZBIO · USD

Health Care · US listing · 🇺🇸 United States

Compare

28.57

+1.10%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$10.0m

FY2022FY2025

Net income

−$377.7m

FY2022FY2025

Free cash flow

−$172.4m

FY2022FY2025

Shareholders' equity

$242.1m

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue$10.0m$5.0m$50.0m—
Research and development$168.1m$139.1m$60.0m$62.7m
Operating income−$211.4m−$163.9m−$37.1m−$76.2m
Net income−$377.7m−$157.0m−$37.1m−$119.3m
Diluted earnings per share-8.12-3.76-0.97-3.11

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets$383.6m$370.0m$68.2m$74.6m
Cash and short-term investments$343.2m$350.8m$56.9m$67.2m
Total liabilities$141.5m$57.5m$293.9m$266.9m
Debt$1.1m—$20.3m—
Shareholders' equity$242.1m$312.5m−$225.7m−$192.3m
Shares outstanding46m42m38m38m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−$172.3m−$119.7m−$30.5m−$65.7m
Capital spending−$18,000−$131,000−$17,000−$2.2m
Free cash flow−$172.4m−$119.8m−$30.5m−$67.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.0m—$10.0m——$10.0m$5.0m—
Operating income−$107.7m−$77.4m−$238.0m−$52.6m−$55.2m−$37.3m−$55.6m−$41.0m
Net income−$111.5m−$81.0m−$240.4m−$51.5m−$52.2m−$33.6m−$52.6m−$38.6m
Diluted earnings per share-1.77-1.28-5.17-1.11-1.12-0.72-1.26-0.92
Cash from operations−$57.0m−$75.0m−$52.0m−$41.0m−$41.0m−$37.0m−$38.0m−$31.0m
Capital spending——−$30.0m−$5.0m————
Free cash flow——−$82.0m−$46.0m————
Total assets$701.7m$747.7m$383.6m$322.0m$293.1m$333.8m$370.0m$403.4m
Cash and short-term investments$643.1m$717.2m$343.2m$290.9m$273.3m$312.4m$350.8m$386.8m
Debt$823,000$266.8m$1.1m$618,000$793,000$908,000$785,000$384,000
Shareholders' equity$247.1m$335.8m$242.1m$196.4m$239.6m$284.3m$312.5m$359.4m

Financial ratios

Data as of 5 Nov 2026

FY2025FY2024FY2023FY2022
Operating margin-3704.9%-3131.2%-54.3%—
Net margin-3777.4%-3139.8%-74.2%—
Return on equity-156.0%-50.2%16.4%62.0%
Return on assets-98.5%-42.4%-54.4%-159.9%
Free cash flow yield-13.0%-10.1%-2.8%-5.8%
Revenue growth100.0%-90.0%——
Earnings growth140.6%322.9%-68.9%—
Current ratio5.61x6.21x2.57x2.64x
Debt to equity0.00x0.00x-0.09x-0.00x
Equity ratio63.1%84.5%-331.1%-257.8%
Interest coverage-50.56x———
R&D as a share of sales1680.6%2782.8%120.1%—
Buybacks as a share of market value-11.3%-9.1%0.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income40.5%——
Net income46.8%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-2.1-1.1
Price to sales81.333.0

Market value over time

30 Sept 2024 to 4 Nov 2026, in USD

$706.9m$1.80bn

Share price return

Finished calendar years

20252024
Return281%-49%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.